Literature DB >> 3581491

Effect of betahistine dihydrochloride on induced vestibular nystagmus: a double blind study.

W J Oosterveld.   

Abstract

The effect of betahistine on vestibular nystagmus induced by means of a torsion swing was tested in 10 subjects. Each individual received, in a randomized double-blind study, 3 different single oral dosages of betahistine (8, 16 and 32 mg) on 3 different occasions. Electronystagmographic tracings were taken at different time-intervals after drug intake. At 3-4 hours after a dose of 8 mg betahistine the nystagmus duration was reduced by 35%, after 16 mg betahistine by 48% and after 32 mg betahistine by 59% (mean values). All these differences in dose-response are highly significant (P less than 0.0005). It can be concluded from these results, that a dose of 3 X 8 mg or 3 X 16 mg betahistine daily will be efficacious in maintenance treatment of vertigo, and a dose of 3 X 24 mg betahistine daily will have even more effect.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581491     DOI: 10.1111/j.1365-2273.1987.tb00175.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  4 in total

Review 1.  Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

Authors:  M Lacour; O Sterkers
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Management of acute vertigo with betahistine.

Authors:  R A Bradoo; N K Nerurkar; J B Mhapankar; S F Patil; D G Kute
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2000-04

3.  Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.

Authors:  D Monzani; M R Barillari; M Alicandri Ciufelli; E Aggazzotti Cavazza; V Neri; L Presutti; E Genovese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-12       Impact factor: 2.124

4.  Betahistine in the treatment of Ménière's disease.

Authors:  Michel Lacour; Paul H van de Heyning; Miroslav Novotny; Brahim Tighilet
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.